ABELZETA
Live / Applied — Third extension granted (statement of use) (as of 12 Dec 2025)
What this means for you
Not registered yet, but its 24 Jul 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98098323
- Mark type
- Stylized text
- Filed
- 24 Jul 2023
- Published for opposition
- 07 May 2024
- Attorney of record
- Lauren Beth Emerson
Goods and services
- Class 001 — Chemicals: Excipients for use in the manufacture of pharmaceutical and biological preparations for research and medical use; viral vectors and plasmids for scientific research
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for medical use, namely, for the treatment and prevention of diseases, namely, cancer and autoimmune diseases; pharmaceutical preparations, namely, pharmaceutical preparations for use in the treatment of cancer; pharmaceutical and biological preparations for immunotherapy; pharmaceutical and biological preparations for medical diagnostic use; diagnostic kits consisting primarily of cells for medical or clinical use; viral vectors and plasmids for clinical use; cells for medical use
- Class 040 — Treatment of materials: Custom manufacturing of biological tissue, blood, and cells; custom manufacturing of pharmaceutical preparations for immunotherapy; custom manufacture of pharmaceutical and biological preparations for medical use, namely, for the prevention and treatment of cancer and autoimmune diseases; custom manufacture of viral vectors and plasmids for research and clinical use; custom manufacture of excipients for use in the manufacture of pharmaceutical and biological preparations for research and medical use
- Class 044 — Medical, beauty and agricultural services: Cell therapy services, namely, immune cell therapy services and medical treatment using cultured cells; Collection and preservation of biological tissue, blood and cells; providing medical information; providing health information in the field of oncology; providing medical information in the field of pharmaceuticals and cell therapy; medical treatment services, namely, medical treatment of cancer, autoimmune, and inflammatory diseases; medical diagnostic services
Owner
- ABELZETA INC., ROCKVILLE, MD, US
- ABELZETA INC., ROCKVILLE, MD, US
- CELLULAR BIOMEDICINE GROUP, INC., ROCKVILLE, MD, US
Prosecution history
- 12 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Dec 2025 — SOU EXTENSION 3 GRANTED
- 10 Dec 2025 — SOU EXTENSION 3 FILED
- 10 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Nov 2025 — CORRECTED NOA E-MAILED
- 25 Nov 2025 — SOU EXTENSION 2 GRANTED
- 02 Jun 2025 — SOU EXTENSION 2 FILED
- 25 Nov 2025 — DIVISIONAL PROCESSING COMPLETE
- 03 Jun 2025 — DIVISIONAL REQUEST RECEIVED
- 24 Nov 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 24 Nov 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 03 Jun 2025 — TEAS REQUEST TO DIVIDE RECEIVED
- 23 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 23 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED